Eyes with neovascular age-related macular degeneration that switched to faricimab generally had lower rates of lesion activity, longer treatment intervals and stable visual acuity.
A database observational study, presented by Adrian Hunt, MBBS, MBiomedE, FRANZCO, at the American Society of Retina Specialists annual meeting, used data from the Fight Retinal Blindness! Registry based in Sydney to determine the outcomes of switching to faricimab from existing agents between January 2023 and August 2023 in a real-world setting for patients with neovascular AMD.
Of the 297 eyes included in the study